Bayer (FRA:BAYN) has been assigned a €125.00 ($148.81) price target by research analysts at UBS Group in a report released on Monday, www.boersen-zeitung.de reports. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target indicates a potential upside of 17.64% from the company’s previous close.
A number of other research firms have also commented on BAYN. Barclays set a €105.00 ($125.00) price target on shares of Bayer and gave the company a “sell” rating in a research report on Monday, November 6th. Goldman Sachs Group set a €125.00 ($148.81) price target on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, November 7th. Berenberg Bank set a €124.00 ($147.62) price target on shares of Bayer and gave the company a “neutral” rating in a research report on Friday, November 3rd. Jefferies Group set a €137.00 ($163.10) price target on shares of Bayer and gave the company a “buy” rating in a research report on Tuesday, November 14th. Finally, DZ Bank reissued a “buy” rating on shares of Bayer in a research report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of €121.71 ($144.90).
Bayer (BAYN) opened at €106.26 ($126.50) on Monday. Bayer has a 52-week low of €101.45 ($120.77) and a 52-week high of €123.82 ($147.40). The company has a market cap of $88,190.00 and a P/E ratio of 25.12.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/29/bayer-bayn-pt-set-at-125-00-by-ubs-group.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.